Sugi Predict

Sugi Predict / Compounds / SCHEMBL22690199

SCHEMBL22690199

SCHEMBL22690199

Nc1ccc(CN(C(=O)O)S(=O)(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ NT5E P21589 1/20 0.41
▸ RAD52 P43351 1/20 0.40
▸ BACE1 P56817 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ TAS2R14 Q9NYV8 2/20 0.38
▸ MAPT P10636 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ CA2 P00918 3/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CA7 P43166 1/20 0.37
▸ MAOA P21397 2/20 0.36
▸ MAOB P27338 2/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27972519 0.85 CA2 (0.44) ALDH1A1TSHRNT5ERAD52BACE1
SCHEMBL7306368 0.74 GFER (0.44) ALDH1A1TSHRBACE1MAPTGFER
SCHEMBL16699980 0.71 BACE1 (0.50) ALDH1A1BACE1MAPTGFERCYP3A4
SCHEMBL4806015 0.71 RAB9A (0.50) ALDH1A1MAPTCA9CA12MEN1
SCHEMBL8425241 0.71 MAPT (0.48) ALDH1A1TSHRMAPTGFERCYP3A4
SCHEMBL4273616 0.69 CA2 (0.62) ALDH1A1TSHRHSD11B1TAS2R14MAPT
Sulfuric Acid SCHEMBL8642565 0.69 GFER (0.70) ALDH1A1TSHRNT5ERAD52RECQL
4,4'-Methylenedianiline SCHEMBL8646665 0.69 TSHR (0.70) ALDH1A1TSHRNT5ERAD52RECQL
SCHEMBL26099644 0.68 ALDH1A1 (0.42) ALDH1A1TSHRMAPTGFERCYP3A4
SCHEMBL9003487 0.68 HSD11B1 (0.47) TSHRHSD11B1TAS2R14MAPTCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027220-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2026-01-29 — — US claimed
EP-4676540-A1 PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF Novartis AG (CH) 2026-01-14 — — EP claimed
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-12-25 — — US claimed
US-20250339547-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-11-06 — — US claimed
WO-2025111431-A1 ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF LES LABORATOIRES SERVIER (FR) 2025-05-30 — — WO claimed
EP-4525926-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF Novartis AG (CH) 2025-03-26 — — EP claimed
EP-4525925-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF Novartis AG (CH) 2025-03-26 — — EP claimed
EP-4525927-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF Novartis AG (CH) 2025-03-26 — — EP claimed
EP-4525928-A1 ANTIBODY DRUG CONJUGATES Novartis AG (CH) 2025-03-26 — — EP claimed
WO-2024189481-A1 PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2024-09-19 — — WO claimed
US-20240269304-A1 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF LES LABORATOIRES SERVIER (FR) 2024-08-15 — — US claimed
WO-2023225336-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 — — WO claimed
WO-2023223097-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2023-11-23 — — WO claimed
WO-2023225359-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 — — WO claimed
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 — — WO claimed
EP-4251209-A1 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF Novartis AG (CH) 2023-10-04 — — EP claimed
US-20230092679-A1 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-03-23 — — US claimed
WO-2022115477-A1 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2022-06-02 — — WO claimed
EP-3972651-A2 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE Novartis AG (CH) 2022-03-30 — — EP claimed
WO-2020236825-A2 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2020-11-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092679-A1 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE MCL1, BCL9, BAK1 ALDH1A1 296/4885TSHR 4306/4885NT5E 1813/4885
US-20260027220-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF EPHA2, EPHA1, EPHB1 ALDH1A1 951/4885TSHR 553/4885NT5E 3005/4885
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF BID, BCL2, MCL1 ALDH1A1 4315/4885TSHR 3232/4885NT5E 686/4885
US-20250339547-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF MET, BCL3, BCL9 ALDH1A1 2347/4885TSHR 2952/4885NT5E 2806/4885
US-20240269304-A1 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF BCL3, BCL9, BCL2L10 ALDH1A1 1785/4885TSHR 3757/4885NT5E 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.